Eli Lilly & Co is partnering with Chinese online healthcare platform JD Health International Inc. to sell its blockbuster drugs for obesity and diabetes online, following in competitors’ footsteps to drive sales through direct-to-consumer channels.
The tie-up will ease access to Lilly’s drugs treating obesity, diabetes and alopecia through a one-stop service via JD Health’s platform that combines consultations, prescriptions all the way to the drug delivery and subsequent follow-ups, according to an official statement from Lilly’s official WeChat account on Friday. Lilly markets Mounjaro for both obesity and diabetes in China.